NEW YORK (GenomeWeb News) - Warnex Medical Laboratories will develop several new pharmacogenetic assays for Schering-Plough Canada, Warnex said last week.
 
Under the agreement, Warnex said it will supply pharmacogenetic and molecular biology services for Schering-Plough’s clinical trials for cancer and infectious disease therapeutics.
 
Warnex said the company is using its services to identify patients who are more likely to respond to a treatment or who are less likely to have an adverse event.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.